Moderna to Offer $2 Billion in Convertibles to Boost Cancer Work

Moderna plans to raise $2.0B by selling exchangeable debt, with proceeds earmarked for investment in its cancer vaccine business and to repay existing debt. The financing supports near-term funding needs without immediate cash-equity dilution, which is a modestly positive datapoint for liquidity and business runway. Overall market impact is likely limited to the issuer given the transaction size and corporate use of proceeds.